Cat: IPD-X27167

Recombinant Human Claudin-18/CLDN18.2 Protein-VLP Protein (HEK293),His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    Claudin-18/CLDN18.2 Protein-VLP

  • 简介

    Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Alternative Names

    CLDN18; CLDN18.2; Claudin-18.2; Claudin-18; DKFZp564B2062; SFTA5; SFTPJ

  • Species

    Human

  • Source

    HEK293

  • Tag

    C-10*His

  • Purity

    Greater than 90% as determined by SDS-PAGE.

  • Uniprot

    P56856-2

  • Expression Region

    M1-V261

  • AA Sequence

    MAVTACQGLGFVVSLIGIAGIIAATCMDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV

  • Protein Length

    Full Length of Isoform A2

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

Claudin-18 (CLDN18) is a tight junction protein that plays a critical role in maintaining epithelial barrier function and cell polarity. Its expression is predominantly observed in gastric epithelial cells, making it a significant marker for gastric adenocarcinomas, particularly the CLDN18.2 isoform. The overexpression of CLDN18.2 in various gastric cancer types has drawn attention to its potential as a target for immunotherapy. Recent research has focused on developing recombinant protein-based vaccines and therapeutic agents aimed at eliciting a robust immune response against CLDN18.2-expressing tumors. Virus-like particles (VLPs) serve as an effective platform for displaying antigens due to their ability to mimic natural viruses while being non-infectious and highly immunogenic. By utilizing CLDN18.2 as a target antigen in VLP systems, studies aim to enhance the immune response by presenting the antigen in its native conformational context, thereby improving T-cell activation and potential tumor destruction. The exploration of CLDN18/CLDN18.2 VLP recombinant proteins not only provides insights into targeted cancer therapies but also underscores the promise of VLP technology in developing next-generation cancer vaccines, ultimately contributing to improved patient outcomes in gastric cancer treatment.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US